Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Maia Biotechnology Inc MAIA

Healthcare Biotechnology
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces... see more

Recent & Breaking News (NYSEAM:MAIA)

MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 8, 2022

MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022

Business Wire September 6, 2022

MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Business Wire August 22, 2022

MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)

Business Wire August 2, 2022

MAIA Biotechnology Announces Closing of Initial Public Offering

Business Wire August 1, 2022

MAIA Biotechnology Announces Pricing of Initial Public Offering

Business Wire July 27, 2022